SCHEMBL14737463

SCHEMBL14737463

COCCn1nc(-c2cnc3c(n2)c(C(=O)O)cn3COCC[Si](C)(C)C)c2ccc(Cl)cc21

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SYK P43405 7/20 0.40
GUCY1A1 Q02108 2/20 0.37
GUCY1B1 Q02153 2/20 0.37
DGAT1 O75907 1/20 0.36
KDM4C Q9H3R0 2/20 0.36
PTGER4 P35408 1/20 0.36
MAPT P10636 1/20 0.34
KMO O15229 1/20 0.34
JAK2 O60674 2/20 0.34
JAK1 P23458 2/20 0.34
PTPN1 P18031 1/20 0.33
NR3C1 P04150 1/20 0.33
TYK2 P29597 1/20 0.33
JAK3 P52333 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14738237 0.93 SYK (0.39) SYKDGAT1KDM4CMAPTKMO
SCHEMBL14737956 0.92 KDM4C (0.44) SYKDGAT1KDM4CPTGER4MAPT
SCHEMBL14737694 0.91 SYK (0.38) SYKDGAT1KDM4CMAPTKMO
SCHEMBL14737410 0.90 SYK (0.48) SYKDGAT1KDM4CMAPTJAK2
SCHEMBL14737753 0.89 KDM4C (0.38) SYKKDM4CKMOJAK2NR3C1
SCHEMBL14737970 0.89 SYK (0.37) SYKDGAT1KDM4CMAPTKMO
SCHEMBL14737316 0.87 SYK (0.35) SYKDGAT1KDM4CJAK2JAK1
SCHEMBL14738715 0.85 SYK (0.41) SYKDGAT1KDM4CPTGER4JAK2
SCHEMBL14751052 0.84 JAK2 (0.47) SYKGUCY1A1GUCY1B1JAK2JAK1
SCHEMBL14751283 0.84 SYK (0.44) SYKDGAT1MAPTJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2763990-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2017-02-22 EP disclosed
EP-2763990-A1 PYRROLOPYRAZINE KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-08-13 EP disclosed
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 US disclosed
WO-2013030138-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-07 WO disclosed
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS SYK, ZAP70, JAK1 SYK 1/4885GUCY1A1 694/4885GUCY1B1 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.